NASD · Healthcare · Biotechnology · USA
Voyager Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases including Alzheimer's disease, Friedreich's ataxia, and Parkinson's disease. The company's pipeline includes wholly-owned tau-targeting programs and collaborative programs with partners such as Neurocrine and Novartis, leveraging its TRACER platform for brain penetration through intravenous dosing.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Voyager Therapeutics Inc stock.
Undervalued: intrinsic value $2.35 per share, market price $1.52, margin of safety 35.4% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $2.35; the price of $1.52 is 35% below that value.
17 more funds hold it; the full list is part of the paid plan.
10 more in this industry show a wider margin of safety.
VYGR is undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.35; the price of $1.52 is 35% below that value.
$2.35 per share (as of the 2026-11-17 close), against a market price of $1.52. That is a margin of safety of 35.4%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.